ALPROLIX®: the first EHL FIX
WITH >10 years OF REAL-WORLD EXPERIENCE1–3
Click to Explore the BODY of ALPROLIX evidence
USA flag icon Canada flag icon Multi-centre qualitative survey UK flag icon SHL switch Europe flag icon European chart review Whole-country switch Ireland flag icon Previous FIX switch France flag icon
Scalpel icon Surgery Syringe icon On-demand to prophylaxis

Surgery

  • Primary Outcomes
  • Safety
  • Study design

EFFECTIVE HAEMOSTASIS DURING
SURGERY IN A REAL-WORLD SETTING10

A single-centre retrospective review in Ireland of male and female patients with
haemophilia B of all severities (N=56) who underwent major or minor surgery
and received ALPROLIX reported:10

of 11 major surgeries
had no excessive or
unexpected bleeding

of 131 minor
surgeries had
no haemostatic
complications*

of all major surgeries
in the post-operative period
had haemostasis
rated as 'excellent'
(9/11) or 'good' (2/11)†

Surgery

  • Primary Outcomes

EFFECTIVE HAEMOSTASIS DURING
SURGERY IN A REAL-WORLD SETTING10

A single-centre retrospective review in Ireland of male and female patients with
haemophilia B of all severities (N=56) who underwent major or minor surgery
and received ALPROLIX reported:10

of 11 major surgeries
had no excessive or
unexpected bleeding

of 131 minor
surgeries had
no haemostatic
complications*

of all major surgeries
in the post-operative period
had haemostasis
rated as 'excellent'
(9/11) or 'good' (2/11)†

*Difficulty in achieving intra-procedural haemostasis was reported for one surgical dental extraction in a female patient with mild haemophilia; no additional ALPROLIX injections were required, and she was treated with tranexamic acid for 5 days post procedure with no complications.10 †Haemostatic efficacy intraoperatively was not formally assessed at time of procedure, but procedure notes were reviewed retrospectively by study investigators.10

  • Safety

PERIOPERATIVE TREATMENT WITH ALPROLIX
WAS WELL TOLERATED10

Shield icon

No thrombosis10

No development of inhibitors10

No serious adverse events deemed related to ALPROLIX10

For complete safety information please refer to the ALPROLIX SmPC




  • Study design

EFFECTIVE HAEMOSTASIS DURING
SURGERY IN A REAL-WORLD SETTING10

A retrospective review of people with haemophilia B ≥18 years who underwent
a major or minor surgery and received ALPROLIX perioperatively10

Surgery 3 Surgery 3

*No female patients were included in the ALPROLIX clinical trial, but their perioperative management was safely managed within this study.10


*Difficulty in achieving intra-procedural haemostasis was reported for one surgical dental extraction in a female patient with mild haemophilia; no additional ALPROLIX injections were required, and she was treated with tranexamic acid for 5 days post procedure with no complications.10 †Haemostatic efficacy intraoperatively was not formally assessed at time of procedure, but procedure notes were reviewed retrospectively by study investigators.10

Safety information References
Multi-centre qualitative survey SHL switch European chart review Whole-country switch Previous FIX switch Surgery On-demand to prophylaxis